Facebook
Twitter
LinkedIn
ForwardBreast Radiotherapy – Harnessing New Technology to Mitigate Toxicity
Over the past decade, breast cancer radiotherapy has increasingly focused on technology to improve treatment precision and limit toxicity. Rapid developments in the technological delivery of radiation via both volumetric arc therapy and proton beam radiation have shown promise in improving target coverage and normal tissue sparing for breast cancer patients. Cutting edge innovations, including MR-guided radiotherapy and FLASH technology are now being explored as means to further improve treatment precision and decrease toxicity. The purpose of this talk is to highlight and discuss these advances in radiotherapy, review the existing evidence to support their use in the treatment of breast cancer, and detail specific patient populations that are most likely to benefit. Discussion will also focus on ongoing and future research aimed at improving our understanding and utilization of these novel advances in care.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, Endocrinologists, Pulmonologists, Otolaryngologists, Urologists, Colorectal Surgeons, Neurologists, General Surgeons, Orthopedic Surgeons, Breast Surgeons, General Practitioners, Obstetricians and Gynecologists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Review the indications and clinical potential of volumetric arc therapy (VMAT) and proton therapy for mitigating the late effects of breast radiotherapy.
- Assess the current state and future possibilities of MR-guided radiotherapy and FLASH technology for breast cancer.
- Analyze ongoing and future opportunities for research/learning.
Rachel Jimenez, M.D.
Chair, Quality and Safety
Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts
Rachel Jimenez, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Guilherme Rabinowits, M.D., conference director of this educational activity, is a consultant/advisor with Sanofi-Genzyme, Regeneron, Castle Biosciences and Boston Gene.
All of the relevant financial relationships listed for this individual has been mitigated.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 General certificate of attendance
- 0.75 Nurse Practitioners
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
